Amgen and UCB have announced results from the fourth year of a phase 2 study showing the efficacy and safety of a second course of treatment with Evenity (romosozumab), an investigational agent for ...

Amgen and UCB’s bone-forming antibody drug candidate Evenity™ (romosozumab) met primary and secondary endpoints in the Phase III ARCH study in postmenopausal women with osteoporosis at high risk of ...

This event-driven study evaluated 12 months of EVENITY treatment (210 mg, administered monthly), followed by at least 12 months of alendronate treatment (70 mg), compared with alendronate treatment ...

Amgen and UCB announced that the US Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture. The ...